CVRx, Inc. (CVRX) News

CVRx, Inc. (CVRX): $7.45

0.37 (-4.73%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Filter CVRX News Items

CVRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CVRX News Highlights

  • For CVRX, its 30 day story count is now at 5.
  • Over the past 19 days, the trend for CVRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about CVRX are BEAT, DEC and DRUG.

Latest CVRX News From Around the Web

Below are the latest news stories about CVRX INC that investors may wish to consider to help them evaluate CVRX as an investment opportunity.

CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast. A live audio webcast of the c

Yahoo | December 27, 2023

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | December 27, 2023

CVRx receives FDA approval for expanded labeling of Barostim

U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF dataMINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has approved revised Instructions For Use (IFU) for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. “We are very pleased to receive this important validat

Yahoo | December 26, 2023

CVRx (CVRX) Is Up 10.17% in One Week: What You Should Know

Does CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 18, 2023

CVRx (CVRX) is on the Move, Here's Why the Trend Could be Sustainable

CVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Yahoo | December 8, 2023

CVRx (CVRX) Moves 7.1% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | December 4, 2023

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Maybe you could find out which stocks a well-known company that has been successful for a long time really likes -- a company such as Johnson & Johnson (NYSE: JNJ). Here are the three stocks that J&J is betting the most on. As of Sept. 30, 2023, Johnson & Johnson's biggest investment was in Legend Biotech (NASDAQ: LEGN).

Yahoo | November 16, 2023

CVRx to Present at the 35th Annual Piper Sandler Healthcare Conference

MINNEAPOLIS, Nov. 15, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. The Company is scheduled to present at 11:00am Eastern Time the same day via webcast. A live aud

Yahoo | November 15, 2023

CMS Increases Outpatient Payment for Barostim Procedure

MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that Centers for Medicare and Medicaid Services (CMS) has reassigned the Barostim implant procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. In the 2024 OPPS final rule, Barostim was reassigned to New Technology APC 1580, which carries an average paymen

Yahoo | November 3, 2023

What Makes CVRx (CVRX) a New Strong Buy Stock

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | October 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!